Tesamorelin Peptide: Benefits, Dosing, and What the Research Shows [2026]

TLDR: What You Need to Know About Tesamorelin

Tesamorelin is a 44-amino-acid peptide that stimulates your pituitary gland to produce more growth hormone naturally. The FDA approved it in 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-positive patients. In the LIPO-010 trial, patients taking tesamorelin lost an average of 17.5% of their visceral fat over 26 weeks compared to a 5% increase in the placebo group.

The standard dose is 2mg injected subcutaneously once daily, typically in the abdomen. It costs between $800 and $1,500 per month depending on whether you use the brand name or a compounded version. You need a prescription from a licensed provider.

Unlike direct growth hormone injections, tesamorelin works through your body's own feedback loops. This means it stimulates a more natural pulsatile release of GH and carries a lower risk of supraphysiological hormone levels.

What Is Tesamorelin and Why Do People Use It?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone with a trans-3-hexenoic acid modification that increases its stability and half-life. The FDA approved it specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a condition where antiretroviral drugs cause abnormal fat accumulation around internal organs.

Outside its FDA-approved indication, tesamorelin has gained attention in the anti-aging and body composition optimization communities. Clinicians at hormone optimization clinics sometimes prescribe it off-label for patients with elevated visceral fat, low IGF-1 levels, or age-related changes in body composition.

Tesamorelin is not a weight loss drug in the traditional sense. It specifically targets visceral adipose tissue, the deep fat surrounding your organs, rather than subcutaneous fat or overall body weight. This distinction matters because visceral fat is the type most strongly linked to cardiovascular disease, insulin resistance, and metabolic syndrome.

How Does Tesamorelin Work in the Body?

Tesamorelin binds to GHRH receptors on the anterior pituitary gland and stimulates the synthesis and release of endogenous growth hormone. A 2010 study in the Journal of Clinical Endocrinology and Metabolism found that tesamorelin increased mean GH levels by approximately 82% from baseline in treated patients. This mechanism is fundamentally different from exogenous GH administration because it preserves the body's natural pulsatile release pattern.

Once growth hormone enters circulation, it acts on the liver and other tissues to produce insulin-like growth factor 1 (IGF-1). The elevated IGF-1 drives lipolysis, the breakdown of stored fat, particularly in visceral adipose depots. Research published in the New England Journal of Medicine showed that tesamorelin selectively reduces trunk fat while preserving lean muscle mass and subcutaneous fat distribution.

The pulsatile GH release triggered by tesamorelin also activates downstream pathways involved in protein synthesis, collagen production, and cellular repair. These secondary effects may explain why some users report improvements in skin quality, sleep, and recovery alongside the primary fat reduction benefits.

What Does the Clinical Research Actually Show?

Tesamorelin has better clinical evidence than most peptides used in practice. Two major Phase III trials, LIPO-010 and LIPO-011, enrolled over 800 HIV-positive patients with lipodystrophy and demonstrated statistically significant visceral fat reduction. In LIPO-010, trunk fat decreased by 15.2% at 26 weeks in the tesamorelin group versus a 5% increase in placebo.

A 2014 meta-analysis published in PLoS ONE pooled data from multiple trials and found that tesamorelin reduced visceral adipose tissue by an average of 28 cm squared on CT imaging. The analysis also confirmed improvements in triglyceride levels and patient-reported body image scores. Importantly, the fat loss reversed within 12 weeks of discontinuation, suggesting the drug needs to be taken continuously for sustained results.

Beyond fat reduction, research has explored tesamorelin's effects on liver fat and cognitive function. A 2019 study in the Journal of Hepatology found that tesamorelin reduced liver fat fraction by 37% in HIV patients with nonalcoholic fatty liver disease. A separate 2020 trial published in Neurology showed improved cognitive performance in older adults with mild cognitive impairment.

What Is the Correct Tesamorelin Dosage?

The FDA-approved dose of tesamorelin is 2mg injected subcutaneously once daily, typically in the abdomen. This was the dose used across all major clinical trials, and published data on other dosing approaches is thin. The injection should be given at the same time each day, ideally in the morning before eating, to align with the body's natural cortisol and GH cycles.

For the brand-name product (Egrifta SV), reconstitution is straightforward. Each kit contains pre-measured vials of lyophilized powder and sterile water for injection. You add the diluent to the powder vial, gently swirl until dissolved, and draw the full contents for injection.

Compounded tesamorelin may come in different concentrations requiring reconstitution with bacteriostatic water. Always follow the specific instructions provided by your compounding pharmacy and prescribing clinician. Most compounded versions use 2mg to 3mg vials reconstituted with 1 to 2mL of BAC water.

What Are the Side Effects of Tesamorelin?

In clinical trials, tesamorelin was generally well tolerated. The most commonly reported side effect was injection site reactions, occurring in approximately 8.5% of patients in the Phase III trials. These reactions included redness, itching, swelling, and pain at the injection site, and they were typically mild and resolved on their own.

Other reported side effects included joint pain (arthralgia) in about 3.5% of patients, peripheral edema in 3.2%, and paresthesia (tingling or numbness) in 2.8%. These effects are consistent with elevated growth hormone levels and are generally dose-dependent. Some patients also reported transient increases in blood glucose levels, which is expected given GH's counter-regulatory effects on insulin.

Tesamorelin is contraindicated in pregnancy, in patients with active malignancy, and in those with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor surgery. Long-term safety data beyond 12 months is limited, so ongoing monitoring of IGF-1 levels and glucose metabolism is recommended during extended use.

How Much Does Tesamorelin Cost and Where Can You Get It?

Brand-name Egrifta SV carries a list price of approximately $1,200 to $1,500 per month, making it one of the more expensive peptide therapies. Most commercial insurance plans do not cover tesamorelin for off-label use, although some HIV patients may obtain coverage through specialty pharmacy programs or manufacturer copay assistance programs provided by Theratechnologies.

Compounded tesamorelin is available through 503A and 503B compounding pharmacies at significantly lower prices, typically ranging from $200 to $500 per month depending on the source, dosage, and quantity. Since the FDA's 2023 guidance on compounded peptides, availability of compounded tesamorelin has fluctuated. Check with your prescribing provider about current sourcing options.

You need a valid prescription from a licensed healthcare provider to obtain tesamorelin in any form. Telehealth clinics specializing in hormone optimization and peptide therapy can evaluate you and prescribe it if clinically appropriate. Be cautious of any source selling tesamorelin without requiring a prescription, as this indicates it is sold as a research chemical and not intended for human use.

Frequently Asked Questions About Tesamorelin

Is tesamorelin the same as growth hormone?

No. Tesamorelin stimulates your pituitary gland to produce and release its own growth hormone naturally. Direct GH injections (somatropin) bypass this feedback loop entirely.

The practical difference is that tesamorelin produces a more physiologic, pulsatile GH release rather than a sustained supraphysiologic spike.

How long does it take tesamorelin to work?

Most clinical trials measured outcomes at 26 weeks. IGF-1 levels typically increase within the first 2 to 4 weeks of treatment. Measurable reductions in visceral fat usually become apparent on imaging at 8 to 12 weeks, with full effects seen at 6 months.

Can women take tesamorelin?

Yes, tesamorelin has been studied in both men and women. However, it is absolutely contraindicated during pregnancy and should not be used by women who are pregnant or planning to become pregnant. Women of childbearing age should use reliable contraception during treatment.

Does tesamorelin build muscle?

Tesamorelin's primary effect is visceral fat reduction, not direct muscle building. However, the elevated GH and IGF-1 levels may support lean mass preservation and modest improvements in body composition. It is not a replacement for resistance training or anabolic interventions for muscle hypertrophy.

What happens when you stop taking tesamorelin?

Clinical data shows that visceral fat tends to return within 12 weeks of discontinuing tesamorelin. The 2014 meta-analysis confirmed that treatment effects were not maintained after stopping the drug. This means tesamorelin requires ongoing use for sustained benefits.

Can you stack tesamorelin with other peptides?

Some clinicians combine tesamorelin with ipamorelin, a growth hormone-releasing peptide (GHRP), to enhance GH output through dual-receptor activation. There is limited clinical data on this specific combination, and dosing should be determined by a qualified provider who can monitor your IGF-1 levels and metabolic markers.